Anika Therapeutics’ (ANIK) Sell (D-) Rating Reiterated at Weiss Ratings

Weiss Ratings reiterated their sell (d-) rating on shares of Anika Therapeutics (NASDAQ:ANIK) in a research report released on Thursday morning,Weiss Ratings reports.

Separately, Barrington Research restated an “outperform” rating and issued a $15.00 target price on shares of Anika Therapeutics in a research note on Tuesday, September 23rd. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $18.00.

Anika Therapeutics Stock Performance

Shares of ANIK stock opened at $9.75 on Thursday. The stock’s 50-day simple moving average is $9.19 and its 200-day simple moving average is $10.58. The firm has a market capitalization of $140.60 million, a PE ratio of -2.35 and a beta of 0.62. Anika Therapeutics has a fifty-two week low of $7.87 and a fifty-two week high of $24.12.

Hedge Funds Weigh In On Anika Therapeutics

A number of hedge funds have recently bought and sold shares of the business. Strs Ohio purchased a new position in Anika Therapeutics during the third quarter worth approximately $131,000. Williams & Novak LLC purchased a new position in Anika Therapeutics during the third quarter worth approximately $102,000. CWM LLC boosted its position in Anika Therapeutics by 526.6% during the third quarter. CWM LLC now owns 7,457 shares of the biotechnology company’s stock worth $70,000 after purchasing an additional 6,267 shares in the last quarter. Assenagon Asset Management S.A. purchased a new position in Anika Therapeutics during the third quarter worth approximately $431,000. Finally, Opaleye Management Inc. boosted its position in Anika Therapeutics by 49.1% during the second quarter. Opaleye Management Inc. now owns 588,797 shares of the biotechnology company’s stock worth $6,229,000 after purchasing an additional 193,797 shares in the last quarter. Hedge funds and other institutional investors own 91.53% of the company’s stock.

Anika Therapeutics Company Profile

Anika Therapeutics, Inc, a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally.